From October 1, 2023 to December 31, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for $0 million under the buyback announced on September 18, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | 0.00% | +3.68% | -47.78% |
30/06 | Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired. | CI |
24/06 | Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.78% | 29.43M | |
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |
- Stock Market
- Equities
- ENLV Stock
- News Enlivex Therapeutics Ltd.
- Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.